PATENT CLAIM ANALYSIS

Application Number: 16020469
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["530", "351000"]

Abstract:
The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Claim (Index 6):
The construct according to any of the preceding claims, wherein said mutated cytokine copy is selected from the group consisting of TNF Y87Q, TNF Y87F, TNF I97A, TNF I97S, TNF Y115A, TNF Y115G.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 94.0
- Lexical Diversity: 2.2069
- Patent Class: 530.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14905354', '15883925', '14372730', '15717205', '15278854']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.798719933481774
- 35 USC 102 Novelty (BERT): 0.6218833365475608
- Combined Prediction Score: 0.7810362737883526
- Mean Citation Score: 506.47091600000016
- Max Citation Score: 751.4879
- Similarity Product: 507.26092590732566

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test